Novartis' Kisqali (ribociclib) Receives Highest Score on the ESMO Magnitude of Clinical Benefit Scale
Shots:
- Novartis’ Kisqali + endocrine therapy has achieved 5 out of 5 scores on ESMO-MCBS- confirming substantial benefit for premenopausal women with HR+/HER2- aBC- based on OS benefit and improved QoL in the P-III MONALEESA-7 study
- Kisqali is also the only CDK4/6 inhibitor to receive a score of 4 out of 5 in combination with fulvestrant for 1L postmenopausal women with HR+/HER2- aBC based on the OS benefit and maintained QoL observed in P-III MONALEESA-3. Additionally- Kisqali + fulvestrant receive a score of 4 out of 5 in a 2L setting based on the MONALEEA-3 study
- New data presented at ESMO 2020 add to the substantial body of evidence further differentiating Kisqali as the only CDK 4/6 inhibitor that improves OS in two P- III trials- with consistent results across patient subgroups- and with QoL benefits. Kisqali in patients with endocrine resistance led to a 30% & 41% reduction in the risk of death in the MONALEESA-3 & -7 studies over standard endocrine therapy respectively
Ref: Novartis | Image: Novartis
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com